Overview

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a Cocktail of Substrates

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Study 516-010 is an open-label Phase 1, drug-drug interaction study evaluating the effect of sitravatinib on probe substrates for CYP450 enzymes and BCRP and P-gp transporters.
Phase:
Phase 1
Details
Lead Sponsor:
Mirati Therapeutics Inc.
Treatments:
Dextromethorphan
Digoxin
Midazolam
Nivolumab
Rosuvastatin Calcium
Warfarin